Altshuler Shaham’s Tvardi Therapeutics TVRD Stock Holding History

Altshuler Shaham’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-404	Closed	-$208K	–	689
2021 Q2	$208K	Hold	404	–	–	﹤0.01%	276
2021 Q1	$316K	Hold	404	–	–	﹤0.01%	171
2020 Q4	$220K	Hold	404	–	–	﹤0.01%	161
2020 Q3	$185K	Hold	404	–	–	﹤0.01%	140
2020 Q2	$249K	Hold	404	–	–	0.01%	117
2020 Q1	$192K	Buy	404 +146	+57%	+$79.3K	0.01%	123
2019 Q4	$150K	Hold	258	–	–	﹤0.01%	172
2019 Q3	$173K	Buy	+258	New	+$214K	0.01%	168

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Altshuler Shaham's TVRD Position: Q3 2021 in Review

Altshuler Shaham sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 404 shares — an estimated $208K sold.

Altshuler Shaham first reported a position in TVRD in Q3 2019 and held it in 8 quarters. The position peaked at $316K in Q1 2021. 168 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

Altshuler Shaham reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
Altshuler Shaham sold 404 Tvardi Therapeutics shares in Q3 2021, an estimated $208K.
Altshuler Shaham first reported a position in Tvardi Therapeutics in Q3 2019 and held it in 8 quarters.
Altshuler Shaham's Tvardi Therapeutics position peaked at $316K in Q1 2021.
168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Altshuler Shaham's 13F filing for Q3 2021, filed 15 Nov 2021.